Carregant...
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
BACKGROUND: The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. METHODS: We performed three open-label, dose-escalation phase 1...
Guardat en:
Publicat a: | N Engl J Med |
---|---|
Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
2015
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490784/ https://ncbi.nlm.nih.gov/pubmed/25830326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1502924 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|